opener

ICA-27243 is less effective at activating KCNQ4 and KCNQ3 Q5. ICA-27243 is a potent and orally active KCNQ2 Q3 potassium channel opener (EC50: 0.38 μM). ICA-27243 also has antiepileptic and anticonvulsant effects.

Aprikalim (RP 52891) is an adenosine triphosphate potassium channel (KATP) opener that protects against nerve damage in a rabbit model of spinal cord ischemia.Aprikalim inhibits vasoconstriction and inhibits the elevation of [Ca2+]i during myocardial paralysis, and can be used to study cardiovascular disease.

Rilmakalim is a potassium channel opener. Rilmakalim shows antivasoconstrictor effect.

1-((3R,4S)-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)chroman-4-yl)pyrrolidin-2-one is an isomer of Rilmakalim, a potassium channel opener (PCO), which can activate ATP-sensitive K+ channels in the heart or other tissues

PCO 400 is an analog of comakalim that acts as a selective and potent ATP-sensitive K+ channel opener.

Flupirtine maleate (Katadolon maleate), a centrally acting non-opioid analgesia, is the salt form of Flupirtine. It is an NMDA receptor antagonist , and also a specific neuronal potassium channel opener.

SG 209 is an analog of nicorandil and acts as a K+ channel opener and nitrate-free coronary vasodilator.

ZM 226600 is an ATP-sensitive potassium channel opener with an EC50 value of 500 nM. ZM226600 has an inhibitory effect on spontaneous bladder activity.

ICA 110381 is a KCNQ2 Q3 potassium channel opener for the treatment of epilepsy

ICA-105665 (PF-04895162) is a potent and orally active opener of neuronal Kv7.2 7.3 and Kv7.3 7.5 potassium channels. ICA-105665 had low cytotoxic potential in human hepatocytes but inhibited liver mitochondrial function and bile salt export protein (BSEP) transport (IC50 of 311 μM). ICA-105665 can penetrate the central nervous system (CNS) and has antiseizure effects [1][2][3][4].

U-89232 is an opener of the cardioselective KATP channel.

KRN 4884 is an opener of the K+ channel. KRN 4884 (0.1-3 μM) activates KATP channels in a concentration-dependent manner (EC50=0.55 μM), in the presence of intracellular ATP (1 mM).

Naminidil is an opener of cyanoguanidine KATP.

Tifenazoxide is an effective and SUR1 Kir6.2 selective KATP channels opener. Tifenazoxide has an anti-diabetic effect, can inhibit glucose-stimulated insulin release in vitro and in vivo.

Y-26763 is a K+ channel opener and active metabolite of Y-27152. This is an ATP-sensitive K+ (KATP) channel activator.

Y-27152 is a prodrug of the KATP (Kir6) channel opener Y-26763 and is a long-acting K+ channel opener.

BMS-191095 hydrochloride is a mitochondrial KATP channel opener. It offers cardioprotective benefits without causing vasodilation or impacting electrophysiology. Its protective mechanisms include prolonging myocardial contraction during ischemia, enhancing contractile function post-reperfusion, and reducing lactate dehydrogenase (LDH) release.

Cromakalim (BRL 34915) is an ATP-dependent K(+) channel opener and a smooth muscle relaxant.Cromakalim has antiepileptic and anticonvulsant activity and may be useful in studies of asthma and disorders associated with vasodilation.

Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1 SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.

KCO-912 is a potent and selective opener of ATP-dependent potassium (K ATP) channels. KCO-912 suppresses airways hyperreactivity at doses devoid of cardiovascular effects.

NC00075159 is an opener of human KCNQ4 (Kv7.4) potassium channel.

NS004 is a large-conductance K+ channel opener, it inhibits mitochondrial function in glioma cells.

QO-58 is a Kv7 channel opener with EC50 values of 7.0, 1.0, 5.2, 0.6 μM for Kv7.1, Kv7.2, Kv7.3/7.5, Kv7.4 respectively. QO-58 increases the pain threshold of neuropathic pain in a sciatic nerve CCI in vivo.

Ro 31-7837 is an opener of potassium channel.